Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock
17 févr. 2021 16h05 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer
11 févr. 2021 07h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM; “Molecular Templates” or “MTEM”) today announced that it has entered into a worldwide strategic research...
Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology
19 janv. 2021 08h00 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the...
Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study
21 déc. 2020 16h30 HE
|
Molecular Templates, Inc.
Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to...
Molecular Templates to Participate in Upcoming Virtual Investor Conferences
16 nov. 2020 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
05 nov. 2020 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the...
Molecular Templates to Participate in September Virtual Investor Conferences
03 sept. 2020 08h00 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results
06 août 2020 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the...
Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility
20 juil. 2020 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, July 20, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the...
Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2020 Highlight Evolution of ETB Platform
22 juin 2020 07h30 HE
|
Molecular Templates, Inc.
Update Provided Phase I Study of MT-5111 in HER2-positive Cancers Conference Call and Webcast to Discuss AACR Posters on June 25th at 10:30am Eastern Time AUSTIN, Texas, June 22, 2020 (GLOBE...